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Abstract
Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition and
Allergies (NDA) was asked to deliver an opinion on proline-speciﬁc oligopeptidase (Tolerase® G) as a
novel food ingredient submitted pursuant to Regulation (EC) No 258/97 of the European Parliament and
of the Council, taking into account the comments and objections of a scientiﬁc nature raised by Member
States. The novel food is an enzyme preparation of prolyl-oligopeptidase produced with a genetically
modiﬁed Aspergillus niger self clone strain. The target population is the general adult population. The
results from a bacterial reverse mutation test and of an in vitro chromosome aberration test did not
indicate genotoxicity. The Panel considers that the reported effects observed in a 90-day rat study are
treatment-related effects and can be attributed to the higher energy consumption by these animals.
Taking into account the intended maximum use level for Tolerase® G, its daily consumption would
correspond to 2,746 mg TOS/person or to 39.2 mg TOS/kg body weight (bw) per day, when considering
a default body weight of 70 kg for an adult person. The margin between this value and the dose in the
rats, which caused effects attributable to the excess energy intake, is approximately 45. Noting this
margin, the Panel considers that it is unlikely that such effects would occur in human at the intended use
levels. The Panel concludes that the NF, Tolerase® G, is safe for the intended use at the intended use
level.
© 2017 European Food Safety Authority. EFSA Journal published by John Wiley and Sons Ltd on behalf
of European Food Safety Authority.
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Summary
Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition
and Allergies (NDA) was asked to deliver an opinion on proline-speciﬁc oligopeptidase (Tolerase® G) as
a novel food (NF) ingredient submitted pursuant to Regulation (EC) No 258/971 of the European
Parliament and of the Council, taking into account the comments and objections of a scientiﬁc nature
raised by Member States. The assessment follows the methodology set in Commission
Recommendation 97/618/EC of 29 July 1997 concerning the scientiﬁc aspects and the presentation of
information necessary to support applications for the placing on the market of NFs and NF ingredients
and the preparation of initial assessment reports under Regulation (EC) No 258/97 of the European
Parliament and of the Council. The assessment is based on the data supplied in the original
application, the initial assessment by the competent authority of France, the concerns and objections
of the other Member States and the responses of the applicant.
The NF is an enzyme preparation of prolyl-oligopeptidase produced with a genetically modiﬁed
Aspergillus niger self clone strain. The composition of this enzyme preparation and its production process
including a submerged fermentation do not raise safety concern. The information provided on the
genetic modiﬁcation carried out to obtain the producer strain GEP-44, on the genetic stability of the
production microorganism, the expression of the recombinant protein and on the absence of
recombinant DNA in the NF, do not raise safety concerns.
The target population is the general adult population. The NF is intended to be consumed just before,
during or directly after a meal. The applicant recommends an intake of 40 PPU Tolerase® G per meal
(= 0.916 g enzyme preparation) and daily maximum intake of 120 PPU (2x10E6 PPI) Tolerase® G
(approximately 2.7 g enzyme preparation) which would correspond to three intakes (three meals) per day.
The results from a bacterial reverse mutation test and of an in vitro chromosome aberration test
did not indicate genotoxicity.
In a subchronic oral toxicity study carried out in accordance with OECD Guideline 408 and in
compliance with Good Laboratory Practice (GLP), the enzyme preparation was administered by gavage
to groups with 10 male and 10 female Wistar rats each over a 90-day period in doses of 0 (control
group), 2,000, 7,000 and 20,000 mg/kg body weight (bw) per day, corresponding to 518, 1,813 and
5,180 mg dry weight/kg bw per day. The control group received double distilled water. A signiﬁcantly
higher bilirubin level (+16.7%) was seen at the highest dose in males, signiﬁcantly increased glucose
levels were seen in the mid- and high-dose group of females and increased cholesterol level was seen
in the high-dose females. The Panel considers that the effects on glucose (+16.5%) and cholesterol
(+33%) may be related to the higher calorie intake by female rats. A signiﬁcant increase in relative
weight (+6.4%) of the liver was seen in the high-dose males. For female rats at the highest dose level,
a signiﬁcant increase was seen for both the absolute and relative liver weight (8.4%). The Panel notes
that the increase in relative liver weight was the only consistent ﬁnding among both sex groups. In
both sexes, the relative liver weight of the mid-dose animals was increased, albeit not statistically
signiﬁcant. No treatment-related differences between groups were seen in gross- and histopathology
including the liver and the tissues of the gastrointestinal tract. According to the data provided in the
study report, the three groups of female rats receiving 518, 1,813 and 5,180 mg dry weight of the test
material/kg bw per day did not consume less feed than the control females, resulting to an energy
intake by the females of the high-dose group which was about 9.2% higher than in the control group.
While the mid-dose group in male rats also did not reduce feed intake, high-dose male had a
signiﬁcantly decreased feed consumption. Upon request of European Food Safety Authority (EFSA), the
applicant calculated and compared the total energy intake from the feed and from the test material
between the high-dose and control male rats for the 13 time points when feed intake and body weight
were recorded. According to these calculations, the total energy intake of high-dose male rats was
approximately 3% higher than of the control males.
The Panel considers that the reported effects of signiﬁcantly higher body weight and body weight
gain by high-dose female rats, absolute increased liver weight by high-dose female and relative
increased liver weight of high-dose female and male rats, and the signiﬁcant increase in glucose in
mid-dose female rats, are treatment-related effects and can be attributed to the higher energy
consumption by these animals. In the absence of differences in liver enzyme plasma levels and the
absence of ﬁndings in the histopathology of the liver, the Panel considers that the increases of plasma
1 Regulation (EC) No 258/97 of the European Parliament and of the Council of 27 January 1997 concerning novel foods and
novel food ingredients (OJ L 43, 14.2.1997, p. 1). http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CONSLEG:
1997R0258:20090120:EN:PDF
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glucose and cholesterol observed in high-dose female rats, and the increase in bilirubin in high-dose
males, are not of toxicological concern.
Taking into account the intended maximum use level for Tolerase® G, its daily consumption would
correspond to 2,746 mg TOS/person or to 39.2 mg TOS/kg bw per day, when considering a default body
weight of 70 kg for an adult person. The margin between this value and the dose in the rats, which
caused effects attributable to the excess energy intake, is approximately 45. Noting this margin, the
Panel considers that it is unlikely that such effects would occur in human at the intended use levels.
The Panel concludes that the NF, Tolerase® G, is safe for the intended use at the intended use
level.
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1. Introduction
1.1. Background and Terms of Reference as provided by the European
Commission
On 13 June 2012, the company DSM Food Specialties submitted a request under Article 4 of the
Novel Food Regulation (EC) No 258/972 to place on the market a proline-speciﬁc oligopeptidase
derived from Aspergillus niger as a novel food (NF) ingredient.
On 31 July 2014, the competent authority of France forwarded to the Commission its initial
assessment report, which came to the conclusion that enzyme preparation of prolyl oligopeptidase
produced with a genetically modiﬁed Aspergillus niger strain meets the criteria for acceptance of a
novel food deﬁned in Article (3)1 of Regulation (EC) No 258/97.
On 11 November 2014, the Commission forwarded the initial assessment report to the other
Member States. Several Member States submitted comments or raised objections.
The concerns of a scientiﬁc nature raised by the Member States can be summarised as follows:
• It is not clear from information provided in the application whether the laboratory concerned is
accredited in accordance with an internationally recognised system to carry out the various
analyses. In general, it should be noted that only a testing laboratory accredited for the testing
spectrum in question should be used for analyses in the context of the authorisation or
determination of the substantial equivalence of a novel food.
• The application contains no data on the total protein content or on the purity of the speciﬁc
prolyl oligopeptidase enzyme.
• The applicant is requested to take into account the potential of A. niger to produce mycotoxins
in the production’s HACCP plan and as part of the in-house control practices.
• As it may be assumed that Tolerase® G does not achieve its spectrum of activity until it
reaches the small intestine, it needs to be encased in a special capsule in order to be effective.
Safety and tolerance tests should therefore be carried out in such a way that they reﬂect the
galenic formulation of the end product.
• The Member States expressed concerns and requested clarity regarding the target population.
• The consumption of the product in question should not exceed the acceptable intake levels
determined on the basis of the toxicological study.
• Concerns were expressed about the in vivo efﬁcacy of the product and the potential for
indirect undesirable effects on the dietary compliance of subjects suffering from coeliac
disease.
• Measurement of the degradation rate of the ‘unwanted’ substance gluten via a simulated
gastric ﬂuid test.
• Concerns were expressed with regard to the consumption of the NF by children.
• Concerns were expressed that the NF may also digest collagen and elastin, which have
substantial proportions of proline.
• Aspergillus niger can cause invasive disease, particularly in immunocompromised individuals
and those with leaky guts. It considered colonisation of the human intestine by the strain of
A. niger producing the NF, as stated by the applicant is uncertain. Consumption of mycotoxins,
e.g. ochratoxins, can cause disease, such as nephrotoxicity, or can be fatal if consumed by an
immunocompromised patient population.
• Safety and long-term tolerability of the NF can only be tested in the human context, as there
may be speciﬁc mechanisms in the human gut and with a human diet that cannot be tested in
animal models easily.
In accordance with Article 29(1)(a) of Regulation (EC) No 178/20023, the European Food Safety
Authority (EFSA) is asked to carry out the additional assessment for proline-speciﬁc oligopeptidase as a
novel food in the context of Regulation (EC) No 258/97.
EFSA is asked to carry out the additional assessment and to consider the elements of a scientiﬁc
nature in the comments raised by the other Member States.
2 Regulation (EC) No 258/97 of the European Parliament and of the Council of 27 January 1997 concerning novel foods and
novel food ingredients. OJ L 43, 14.2.1997, p. 1–6.
3 Regulation (EC) No 178/2002 of the European Parliament and of the Council of 28 January 2002 laying down the general
principles and requirements of food law, establishing the European Food Safety Authority and laying down procedures in
matters of food safety. OJ L 31, 1.2.2002, p. 1–24.
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2. Data and methodologies
2.1. Data
The assessment of the safety of this NF is based on data supplied in the original application, the
initial assessment by the competent authority of France, the concerns and objections of the other
Member States and the responses of the applicant (See ‘Documentation provided to EFSA’). In
accordance with Commission Recommendation 97/618/EC,4 the novel food was allocated by the
French Authority to Class 5.2, i.e. genetically modiﬁed (GM) microorganisms and their products, the
host microorganism used for the genetic modiﬁcation has no history of use as food or as a source of
food in the Community under comparable conditions of preparation and intake, i.e. structured schemes
I, II, III, IV, V, VI, VII, XIII, IX, XI, XII and XIII of Commission Recommendation 97/618/EC. In the
current opinion, these structured schemes are listed in Sections 3.1–3.9.
According to the applicant, the novel food called Tolerase® G ‘is intended to be used as ingredient
for food supplements, supporting the degradation of proteins. Since Tolerase® G is a proline-speciﬁc
oligopeptidase, its main activity is exerted on proline-rich proteins, such as gluten, although other
proteins besides gluten are also degraded. Tolerase® G is intended, for example, to be consumed
alongside (potentially) gluten containing food items, to aid in the degradation of gluten in the
gastrointestinal tract, notably in the stomach’. The target population is the general adult population.
This assessment concerns only risks that might be associated with consumption, and is not an
assessment of the efﬁcacy of the NF with regard to any claimed beneﬁt.
2.2. Methodologies
The assessment follows the methodology set out in Commission Recommendation 97/618/EC of 29
July 1997 concerning the scientiﬁc aspects and the presentation of information necessary to support
applications for the placing on the market of novel foods and novel food ingredients and the
preparation of initial assessment reports under Regulation (EC) No 258/97 of the European Parliament
and of the Council.
Considering the nature of this novel food, an enzyme produced by a GM Aspergillus species, part of the
assessment (concerning the genetically modiﬁed microorganism) follows also the EFSA Guidance on the
submission of a dossier on Food Enzymes (EFSA, 2009a) and the EFSA Guidance on the risk assessment
of genetically modiﬁed microorganisms and their products intended for food and feed use (2006).
3. Assessment
3.1. Speciﬁcation of the NF
The NF (‘Tolerase® G’) is a prolyl-oligopeptidase produced with a GM A. niger self clone strain. The
production process includes a submerged fermentation followed by recovery and concentration steps
(downstream processing). The ﬁnal enzyme preparation is a dried granulate obtained after adding up
to 30% maltodextrin. The NF is a white-grey to cream-coloured microgranule with a maximum of 5%
of the particles being smaller than 63 lm.
The prolyl-oligopeptidase (Enzyme Commission number: EC 3.4.21.26; CAS number: 72162-84-6) is
a glycosylated protein (526 amino acids) with a molecular weight of 66 kDa.
This protease speciﬁcally cleaves peptide bonds at the carboxylic site of proline residues and
releases smaller peptides. The activity of the enzyme can be expressed as PPI (protease picomole
international) or PPU (prolyl peptidase units or proline protease units). The assay is based on the
release of p-nitroanilide (pNA) from the synthetic substrate Z-Gly-Pro-pNA (carbobenzoxy-glycyl-
proline-p-nitroanilide) at pH 4.6 and 37°C. One PPI is deﬁned as the amount of enzyme required to
release one picomole of pNA from Z-Gly-Pro-pNA in 1 s under the conditions of the assay. One PPU is
deﬁned as the amount of enzyme required to release one micromole of p-nitroanilide (pNA) from
Z-Gly-pro-pNA in 1 min under conditions of the assay (pH 4.6, 37.0°C). One PPU therefore amounts to
16,667 PPI.
4 Commission Recommendation 97/618/EC: Commission Recommendation of 29 July 1997 concerning the scientiﬁc aspects and
the presentation of information necessary to support applications for the placing on the market of novel foods and novel food
ingredients and the preparation of initial assessment reports under Regulation (EC) No 258/97 of the European Parliament and
of the Council. OJ L 253, 16.9.1997, p. 1–36.
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The temperature optimum of the enzyme is around 50°C. The enzyme is stable for 10 h at 50°C
and pH 5 with approximately 90% residual activity. The enzyme is inactivated after 5 min at 99°C.
At 37°C, it exhibits maximum activity at pH 4.6 and has approximately 60% of its activity at pH 5.5.
At pH values of 7.0 and higher, the enzyme is essentially inactive.
Information on the chemical composition of the prolyl-oligopeptidase (ultraﬁltration concentrate)
has been provided for four batches; one of them has been used for the toxicological studies (Table 1).
The total organic solids (TOS) content is a calculated value derived as 100% minus % water minus %
ash. It reﬂects the organic material isolated together with the target enzyme from the fermentation
broth. Further information on the composition of these total organic solids is not available.
The enzyme activity of the ﬁnal enzyme preparation is being standardised by adding up to 30% of
maltodextrin. According to the applicant, the enzyme activity of the resulting Tolerase® G granulate is
standardised to a level of at least 580,000 PPI/g.
Speciﬁcations for Tolerase® G based on the information provided by the applicant are shown in
Table 2.
Table 1: Chemical compositions provided for four batches of the prolyl-oligopeptidase enzyme
(ultraﬁltration concentrate)
Batch
812023201
Batch
8144031001
Batch
814033701
Batch(a)
JLL 03 006 IDF
Ash (%) 0.25 0.50 0.50 0.41
Water (%) 78.9 72.3 72.5 74.6
TOS (%)(b) 20.9 27.2 27.0 25.0
Protein (%) 14.4 18.9 18.6 17.3
(a): Batch used for the toxicological studies.
(b): The total organic solids (TOS) content is a calculated value derived as 100% minus % water minus % ash.
Table 2: Speciﬁcations for Tolerase® G
Parameter
DSM
Speciﬁcations
Limits for Tolerase® G
Method
Activity > 580,000 PPI/g
(> 34.8 PPU/g)
Spectrophotometric determination of proline-speciﬁc
endoprotease activity with N-carbobenzoxy-glycyl-
proline p-nitroanilide as a substrate
Appearance Microgranulate
Colour Off-white to orange yellowish.
The colour may change from
batch-to-batch
Dry matter > 94% Compendia method mentioned in FCC 9
Appendix II
Gluten < 20 ppm ELISA kit, COFRAC accredited to ISO 17025
Maltodextrin ≤ 30%
Sodium benzoate ≤ 0.1%
Total heavy metals
(as lead)
≤ 10 mg/kg
Lead ≤ 1.0 mg/kg
Arsenic ≤ 1.0 mg/kg
Cadmium ≤ 0.5 mg/kg
Mercury ≤ 0.1 mg/kg
Microbiology
Total aerobic plate
count
≤ 103 CFU/g NF EN ISO 4833
Total yeasts and
moulds
≤ 102 CFU/g NF V08-059 Nov 2002
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The Panel considers that the information provided on the composition, the batch-to-batch variability
and the speciﬁcations of the NF is sufﬁcient and does not raise safety concerns.
3.1.1. Stability of the NF
If stored below 15°C, the product shows a loss of activity of less than 5% over a 12-month period
and is therefore sufﬁciently stable.
The Panel considers that the data provided sufﬁcient information with respect to the stability of the
NF.
3.2. Effect of the production process applied to the NF
The Tolerase® G enzyme preparation is produced by a controlled submerged fermentation of a
selected, pure culture of Aspergillus niger GEP-44.
The enzyme is manufactured according to the EU Food Hygiene Regulation (EC) No 852/2004.
Pursuant to these regulations, Tolerase® G is manufactured in accordance with current Good
Manufacturing Practice for Food (cGMP) and the principles of Hazard Analysis of Critical Control Points
(HACCP). The manufacturing process is certiﬁed according to Food Safety Systems Certiﬁcation 22000
(FSSC 22000). According to the applicant, compliance to Food Hygiene Regulation is regularly
controlled by relevant food inspection services.
The production process consists of the fermentation and a subsequent downstream processing,
comprising recovery, puriﬁcation and concentration. In the ﬁnal enzyme preparation, the enzymatic
activity of the prolyl-endopeptidase is standardised by addition of maltodextrin.
In addition to routine control of the raw materials used in the Tolerase® G fermentation and control
of the ﬁnal product, the applicant has speciﬁc measures in place with regard to the microbiological
purity throughout the process.
At the end of the fermentation, the recombinant production organism is inactivated.
Parameter
DSM
Speciﬁcations
Limits for Tolerase® G
Method
Sulﬁte-reducing
anaerobes
≤ 30 CFU/g NF ISO 15213
Coliforms (a) (b)
Enterobacteriaceae < 10 CFU/g NF V08-054 April 2009
Salmonella Absent in 25 g NF EN ISO 6579
V08-013
Escherichia coli Absent in 25 g XP ISO/TS 16649-3
December 2005
Staphylococcus aureus Absent in 10 g NF EN ISO 6888
Pseudomonas
aeruginosa
Absent in 10 g DFS-SCL-MIP-W-0105
Listeria
monocytogenes
Absent in 25 g NF EN ISO 16140: 2003
Antimicrobial activity Absent JECFA ISSN 1817-7077
Mycotoxins Absent(c) LC–MS/MS method via SGS in-house method 0033-LC,
accredited by the Dutch Accreditation Board
(www.rva.nl) under scope L092 item 29
(a): The term ‘Coliforms’ or ‘Coliform Bacteria’ refers to a group of lactose fermenting, Gram-negative, facultative anaerobic rods
that form acid and
(b): Gas at 35°C in 48 h. This group is used as an indicator for the hygienic status in food industry and quality indicator for water. It
is a non-taxonomic group that developed historically. The description of the group has changed over the time and therefore
also the genera that are included in it. Initially only the genera of Escherichia, Klebsiella, Enterobacter and Citrobacter were
included, whereas the group currently includes 15 genera. These genera are all included in the family of Enterobacteriaceae.
Therefore, the test for Enterobacteriaceae covers also all the microorganisms found in the test for Coliforms.
(c): Below limits of detection: aﬂatoxins B1, B2, G1, G2 (< 0.25 lg/kg), total aﬂatoxins (< 2.0 lg/kg), ochratoxin A
(< 0.20 lg/kg), T-2 Toxin (< 5 lg/kg), zearalenone (< 2.5 lg/kg), fumonisins B1 and B2 (< 2.5 lg/kg).
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Results of polymerase chain reaction (PCR) analyses based on the detection of the gene encoding
the prolyl-endopeptidase have been provided for three batches of the concentrated enzyme to
demonstrate the absence of recombinant DNA.
According to the applicant, all raw materials used in the production of the enzyme meet
speciﬁcations regarding the absence of mycotoxins. Raw materials used in the fermentation or
formulation steps are either tested by the applicant or conﬁrmation on compliance with respective EU
regulations is requested from the suppliers.
A. niger is known to produce ochratoxin A and fumonisins (Blumenthal, 2004; Palencia et al., 2010;
Frisvad et al., 2011). Consequently, these are routinely analysed together with a broader spectrum of
other mycotoxins by the applicant in the NF. According to the speciﬁcations, they must be absent, i.e.
below the limits of detection of the applied analytical method (Table 2). A. niger has been reported to
produce other secondary metabolites such as nigragilline, nigerazine B and malformins (Blumenthal,
2004).
Quantitative data on the contents of these metabolites have not been provided in the application.
In a screening of industrial A. niger strains, malformins were detectable via tandem mass spectrometry
but were not quantiﬁed because of lack of sufﬁcient amounts of pure authentic standards (Frisvad
et al., 2011).
The Panel considers that the production process is sufﬁciently described and does not raise
concerns about the safety of the NF.
3.3. History of the organism used as a source of the NF
A. niger is a fungus belonging to the phylum Ascomycota which has been used for many years in the
food and pharmaceuticals industry to produce enzymes and chemical substances (such as citric acid).
In order to assess the safety of microorganisms (and viruses) for use in food and feed, EFSA has
developed the concept of a Qualiﬁed Presumption of Safety (QPS) (EFSA, 2007). According to EFSA’s
current opinion on the list of biological agents to which the QPS assessment method may be applied, it
does not recommend including A. niger in the QPS list, since some strains may produce the
mycotoxins (EFSA BIOHAZ Panel, 2013).
The NF was tested negative for the presence of mycotoxins at the limits of detection provided in
Section 1 (speciﬁcations).
Genetic Modiﬁcation:
Regarding the following Sections 3.4–3.8 (GMM): EFSA Enzyme Guidance refers to EFSA GMM
Guidance on the risk assessment of genetically modiﬁed microorganisms and their products intended
for food and feed use (2011). This NF would fall under Category 2: Complex products in which both
GMMs and newly introduced genes are no longer present (e.g. cell extracts, most enzyme
preparations). For such applications, Chapter III, Sections B.2.2. and B.4.1. of this guidance apply.
3.4. Effect of the genetic modiﬁcation on the properties of the host
organism
The NF is produced by submerged fermentation of the Aspergillus niger strain GEP-44 stably
expressing the gepA gene of A. niger. To generate the producer strain GEP-44, the gepA gene from
Aspergillus niger G-306 was inserted into predeﬁned loci of the genome of the recipient Aspergillus
niger strain ISO 508 (which is derived from Aspergillus niger GAM53 (DS3045)) and then further
selected for multiple copies of the gepA gene via spontaneous recombination events. The production
strain GEP-44 contains 20 copies of the gepA gene.
The production strain GEP-44 is derived from the DSM0s GAM-ISO strain lineage of A. niger strains
(van Dijck et al., 2003). Both the parental strain GAM53 (DS3045) and the recipient strain (ISO 508)
were approved as suitable host strains for the construction of genetically modiﬁed organisms (GMOs)
belonging to Group I safe microorganisms and as a GMO obtained through selfcloning5 by the Dutch
5 Self-cloning as deﬁned in the European Directive on the Contained Use of Genetically Modiﬁed Microorganisms 98/81/EC
(revision of 90/219/EC): Self-cloning consisting in the removal of nucleic acid sequences from a cell of an organism which may
or may not be followed by reinsertion of all or part of that nucleic acid (or a synthetic equivalent) with or without prior
enzymatic or mechanical steps, into cells of the same species or into cells of phylogenetically closely related species which can
exchange genetic material by natural physiological processes where the resulting microorganism is unlikely to cause disease to
humans, animals or plants. Self-cloning may include the use of recombinant vectors with an extended history of safe use in the
particular microorganisms.
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Authorities (1994). Similarly, the recombinant prolyl-oligopeptidase producer strain GEP-44 has been
classiﬁed by the Dutch authorities as well as the French Genetic Committee as Group I safe
microorganisms and as a GMO self-clone (CGG, 2003; Dutch Authorities, 2003). On this basis, the
strain is approved for large scale production of prolyl-oligopeptidase.
In response to EFSA request to provide detailed information about the genetic modiﬁcations carried
out to obtain the producer strain GEP-44 following the EFSA Guidance on the risk assessment of
genetically modiﬁed microorganisms (GMMs) and their products intended for food and feed use
(2011), the applicant provided information of the characteristic of the vectors used, the history of
previous and further genetic modiﬁcations to obtain the producer strain GEP-44 and the veriﬁcation of
the sequences actually inserted into the chromosome and the copy number of the inserts by Southern
analysis. According to the additional data provided, the Panel considers that the genetic modiﬁcations
do not raise safety concerns.
On the basis of the provided information the Panel concludes that the recombinant production
strain should not be less safe than the original GAM-53 (DS3045) host strain.
3.5. Genetic stability of the genetically modiﬁed microorganism (GMM)
The strains belong to the Aspergillus niger GAM-lineage – from which both the host ISO 508 and
the recombinant prolyl-oligopeptidase production strain GEP-44 were derived. According to the
applicant, the whole GAM-lineage is stored since the 1970s at their laboratory. New cultures are
frequently derived from stock material and tested after many generations on morphological, growth,
production and product characteristics. According to the applicant, these characteristics remain stable
except that after plating out, a low frequency of morphologically dissimilar colonies are found. This is,
however, considered a normal phenomenon observed for the parental as well as the highly selected
industrial strains. The stability of the ISO strain and the prolyl-oligopeptidase production strain does
not differ from the parental GAM strains.
In response to EFSA’s request to provide data on the stability of the speciﬁc strain (GEP-44) that is
the subject of the present application, the applicant provided data on both the phenotypic and genetic
stability. The phenotypic stability of the strain was established by measuring the enzymatic activity of
the prolyl-oligopeptidase in three independent batches of the food enzyme, showing no substantial
differences. The Panel considers that the genetic stability was conﬁrmed by comparing the genotype of
the producer strain GEP-44 at the end of the fermentation with the strain of the original working cell
bank that was used as inoculum for the fermentation and with the recipient strain ISO 508 using PCR
analysis of two key genetic makers related to the enzyme production.
3.6. Speciﬁcity of expression of novel genetic material
The expression vectors were sequenced and the sequence of the prolyl-oligopeptidase was
conﬁrmed. Data of the sequences were also provided upon EFSA request. The size of the protein
product was determined by sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS–PAGE)
and was found to be at the expected value. Activity measurements showed that the enzyme catalysed
the expected enzymatic reaction.
3.7. Transfer of genetic material from the GMM
The inserted gepA gene encoding the prolyl-oligopeptidase is exactly the same as that present in
A. niger by nature. Since the prolyl-oligopeptidase expression unit is integrated into the chromosome
and the genetic material inserted does not contain an Escherichia coli origin of replication or any other
E. coli sequences, the Panel considers that it is unlikely that this genetic material can be transferred
from the A. niger production organism to another, non-related, organism.
The production strain has been recognised both by the French as well as by the Dutch competent
authorities as a strain obtained by self-cloning (CGG, 2003; Dutch Authorities, 2003). Apart from the
overexpression of this gene, no other genes are expressed other than the genes naturally present in
the genome of the recipient strain of A. niger.
Furthermore, three batches of the food enzyme were analysed to ensure the absence of residual
recombinant DNA using primers targeting the gepA gene. The results of the analyses demonstrate that
no recombinant DNA is present in the enzyme preparation.
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3.8. Ability of the GMM to survive in the human gut
Following a request from EFSA to provide information on inactivation of the producer strain after
the fermentation process, the applicant informed that the producer strain is killed by incubating the
biomass with sodium benzoate (0.4% w/w) during up to 6 h at pH 4.0 and 30°C). According to the
applicant, the inactivation efﬁciency is routinely monitored by plating samples in duplicate on
Plate Count Agar plates. Tests results of three batches (EDP812012601, DP812018501 and
EDP812002101) did not ﬁnd colony-forming units of A. niger.
The host organism is effectively inactivated after the fermentation process and no living host cells
are present in the ﬁnal product. Therefore, the Panel considers that colonisation of the human gut
with prolyl-oligopeptidase overexpressing A. niger cells cannot occur.
3.9. Anticipated intake/extent of use of the NF
The intended target population is the adult general population.
According to the applicant, the product is intended to be consumed just before, during or directly
after a meal. The applicant recommends an intake of 40 PPU Tolerase® G per meal (= 0.916 g enzyme
preparation) and a daily maximum intake of 120 PPU (2x10E6 PPI) Tolerase® G (= 2.7 g enzyme
preparation) which would correspond to three intakes (three meals) per day.
3.10. Information from previous exposure to the NF or its source
The NF has no history of food consumption. Various strains of A. niger have been used not only for
food production, particularly for food enzymes (e.g. a-amylase and hemicellulase), but also for the
production of citric and gluconic acid, for glucosamine hydrochloride (EFSA 2009b).
The safety of prolyl-oligopeptidase contained in the Tolerase® G preparation and produced by the
Aspergillus niger GEP-44 has been previously assessed by AFSSA (2005) as a food processing aid in
beer brewing and is approved for this use in France and Denmark (Foedevarestyrelsen, 2006).
3.11. Nutritional information on the NF
Taking into account the composition of the NF and the intended daily intake levels (2.7 g;
approximately 11 kcal), the Panel considers that the consumption of the NF is not nutritionally
disadvantageous.
3.12. Microbiological information on the NF
The Panel considers that the microbiological information provided does not raise safety concerns.
3.13. Toxicological information on the NF
All toxicological tests were carried out using an enzyme preparation (Batch No JLL 03 006 IDF) with
183,334 PPI (= 11 PPU) per gram and with a TOS value of 25.2% (thus 728,335 PPI or 43.7 PPU per
gram of TOS) produced at pilot plant scale. The characteristics were provided in the dossier (Annex 11
of the ‘consolidated dossier’). The Panel considers that the test item used for the toxicity tests was
representative for the NF.
3.13.1. Absorption, distribution, metabolism and excretion
No information was provided.
3.13.2. Genotoxicity
A bacterial reverse mutation test using Salmonella Typhimurium strains TA98, TA100, TA1535 and
TA1537 and the E. coli strain WP2 uvrA was carried out. In initial tests using the ‘plate incorporation
method’, the enzyme preparation induced in strain TA98 with metabolic activation (S9 mix), and in
strains TA1535 and TA1537, without S9 mix an increase in the number of revertants in comparison
with the negative control. At the same time, a dense bacterial layer was detected on the plate. The
Panel considers that this was attributed to the presence of histidine or protein. In a second test
sequence using the ‘treat and plate’ method, the test material did not induce genotoxicity up to the
highest tested dose of 5,000 lg/plate.
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In vitro chromosome aberration testing using human lymphocytes was carried out in accordance
with OECD Guideline 473. In two separate experiments, no increase in the number of cells with
structural chromosome aberrations was observed with or without S9 mix up to the highest tested dose
of 5,000 lg/mL.
The Panel considers that the data do not indicate genotoxicity.
3.13.3. Subchronic toxicity studies
In a subchronic oral toxicity study carried out in accordance with OECD Guideline 408 and in
compliance with GLP, the enzyme preparation was administered by gavage to groups with 10 male and
10 female Wistar rats each over a 90-day period in doses of 0 (control group), 2,000, 7,000 and
20,000 mg/kg body weight (bw)per day, corresponding to 518, 1,813 and 5,180 mg dry weight/kg bw
per day. The control group received double distilled water. Feed (12.2 MJ/kg, 19% protein, 3.3% fat,
4.9% ﬁbre, 6.7% ash) was available ad libitum.
All the animals survived the treatment period and regular observation revealed no clinically relevant
effects. In the functional observation battery (FOB), no adverse effects were observed. In comparison
to the negative control, a signiﬁcantly lower food intake was seen in high-dose males in the ﬁrst week
(16%) and in the last part of the study (7–11%), and for mid-dose males, in the ﬁrst week only. No
statistically signiﬁcant difference in body weight was seen between the male groups. In the high-dose
females, signiﬁcantly higher body weight and body weight gain were seen throughout the study. The
food intake was not signiﬁcantly different between the female groups except for a signiﬁcant decrease
seen in the ﬁrst week for mid- and high-dose females. Both the lower food intake in males and the
higher body weight seen in females could be explained by the increased amount of calories received
through administration of the test compound.
A statistically signiﬁcant decrease in thrombocyte counts and a signiﬁcantly increased mean
corpuscular haemoglobin (MCH) were seen in the mid- and high-dose females in comparison to the
control group. Erythrocytes were signiﬁcantly decreased in the high-dose females. The only statistically
signiﬁcant ﬁndings in female rats in the mid dose were increased MCH and decreased number of
thrombocyte counts. However, the Panel notes that in male rats such an effect was not observed, that
there was no clear dose–response and that the mean value for thrombocyte counts in the female
control group was two standard deviations (SDs) higher than the mean of historical control data and
that the mean value for MCH of the control group was one SD below the mean value of historical
control data.
In clinical chemistry, a signiﬁcantly higher bilirubin level (+16.7%) was seen at the highest dose in
males, but not in females. In females, signiﬁcantly increased glucose levels were seen in the mid- and
high-dose group. Signiﬁcantly increased cholesterol level was seen in the high-dose females. The
Panel considers that the effects on glucose (+16.5%) and cholesterol (+33%) may be related to the
higher calorie intake by female rats.
A signiﬁcant increase in relative weight (+6.4%) of the liver was seen in the high-dose males. For
female rats at the highest dose level, a signiﬁcant increase was seen for both the absolute and relative
liver weight (8.4%). The Panel notes that the increase in relative liver weight was the only consistent
ﬁnding among both sex groups. In both sexes, the relative liver weight of the mid-dose animals was
increased, albeit not statistically signiﬁcant.
No treatment-related differences between groups were seen in gross- and histopathology including
the liver and the tissues of the gastrointestinal tract.
According to the data provided in the study report, the three groups of female rats receiving 518,
1,813 and 5,180 mg dry weight of the test material/kg bw per day did not consume less feed than the
control females, resulting to an energy intake by the females of the high-dose group which was about
9.2% higher than in the control group. While the mid-dose group in male rats also did not reduce feed
intake, high-dose males had a signiﬁcantly decreased feed consumption. Upon request of EFSA, the
applicant calculated and compared the total energy intake from the feed and from the test material
between the high-dose and control male rats for the 13 time points when feed intake and body weight
were recorded. According to these calculations, the total energy intake of high-dose male rats was
approximately 3% higher than of the control males.
The Panel considers that the reported effects of signiﬁcantly higher body weight and body weight
gain by high-dose female rats, absolute increased liver weight by high-dose female and relative
increased liver weight of high-dose female and male rats, and the signiﬁcant increase in glucose in
mid-dose female rats, are treatment-related effects and can be attributed to the higher energy
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consumption by these animals. In the absence of differences in liver enzyme plasma levels and the
absence of ﬁndings in the histopathology of the liver, the Panel considers that the increases of plasma
glucose and cholesterol observed in high-dose female rats, and the increase in bilirubin in high-dose
males, are not of toxicological concern.
3.13.4. Human studies
The applicant provided three human studies conducted with prolyl-oligopeptidase derived from
A. niger and produced by the applicant:
In a human intervention study with a prolyl-oligopeptidase derived from A. niger (Tack et al.,
2013), 16 diagnosed coeliac patients were fed slices of toast containing a total of 7 g gluten along
with the enzyme preparation (168 PPU) in an initial phase (safety phase) lasting 14 days. Following a
14-day washout phase, 14 patients were divided into two groups and given slices of toast containing
7 g gluten combined with the enzyme preparation or a placebo over a further 14-day period (efﬁcacy
phase). Two patients who had participated in the ﬁrst phase were excluded from the second phase on
ethical grounds because their coeliac symptoms had worsened. According to the article, the enzyme
preparation was well tolerated by the participants during the study, although in the second phase
there were no differences between the two groups with regard to the coeliac parameters tested
(symptom questionnaire, histological and immune parameters of intestinal mucosal biopsy, serum
antibodies and adverse effects). The Panel considers that this study does not provide relevant
information for the safety of the novel food.
In a randomised double-blind placebo-controlled cross-over trial, 18 adult gluten-sensitive
volunteers received a nasogastric tube and consumed a gluten-free breakfast added with 0.5 g of
gluten (as ‘hidden gluten’) and 166 kPPI, 83 kPPU of Tolerase® G enzyme or placebo with a 1-week
washout period in between. In the evening after each test day, subjects were asked to complete a
gastrointestinal symptom rating scale (GSRS). The GSRS included 15 items and used a 7-point Likert
scale in which 1 represents no symptoms and 7 the highest level of symptoms. A statistical analysis
was performed using SPSS statistics 23 on the intention-to-treat population using Wilcoxon signed rank
paired test at a = 0.05 with a Bonferroni correction to detect signiﬁcant differences. No signiﬁcant
differences were observed in GSRS scores between the different test conditions (porridge with
placebo, low-dose and high-dose Tolerase® G). The Panel notes that only a summary of the
unpublished study was provided (DSM, 2016).
In addition a randomised, double-blind, placebo-controlled, cross-over study was performed with 12
healthy volunteers (18–45 years of age) receiving 6.1 mL Aspergillus niger-derived prolyl endoprotease
with 1.6 Mio PPI (96 PPU) produced by the applicant or placebo (Salden et al., 2015). At least 1-week
washout was between two test days when subjects received a low calorie gluten containing meal plus
the enzyme preparation or placebo and a high calorie gluten containing meal plus the enzyme
preparation or placebo. The meal was administered together with the enzyme preparation or the
placebo transnasally through a triple lumen catheter. The two distal lumens were positioned 5 and
15 cm distal to the pylorus to obtain samples of the content from the stomach and the duodenum,
respectively. The primary objective was to assess the efﬁcacy on gluten degradation in a low and high
calorie meal in healthy subjects. At the end of each test day, study participants were asked to ﬁll a
‘Symptoms Diary’ questionnaire with eight items related to gastrointestinal symptoms (abdominal
discomfort, abdominal pain, abdominal distension, constipation, diarrhoea, ﬂatus, eructation and
nausea) and rated them on a 5-point Likert scale. Other study objectives were to investigate the
presence of the Aspergillus niger-derived enzyme in the stomach and the duodenum and
gastrointestinal symptoms. The article reported that there were no statistically signiﬁcant differences
between gastrointestinal symptoms of the verum and the placebo groups. Since the data were not
presented in the published article, the applicant provided the detailed information in response to a
request of EFSA, conﬁrming the information provided in the published article. To assess the presence
of the enzyme in gastric and duodenal samples, the protein fraction from such samples was put on a
SDS-PAGE and subsequently stained with Coomassie Blue. According to the article, the enzyme could
be shown on the gel in 14 out of 15 gastric samples, but in no sample obtained from the duodenum.
The Panel notes that the staining presented in the article may suggest faint signals at 10 and 15 min
after start of the meal infusion, but that there was no signal after 30 min. The Panel considers that the
data provided in this study indicate degradation of the enzyme in duodenum and that the consumption
of 1.6 Mio PPI of this enzyme did not cause acute gastrointestinal symptoms in healthy subjects.
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3.14. Allergenicity
The applicant determined on the basis of bioinformatic methods (sequence homology) using the
database allermatch (www.allermatch.org) that prolyl-oligopeptidase derived from A. niger does not
manifest any sequence identity of greater than 35% with known allergens over a segment of at least
80 amino acids. In silico analysis of pepsin digestibility of the protein sequence using the program
‘PeptideCutter’ (ExPASy) performed by the applicant suggested degradability of the enzyme.
A 2.4% prevalence of sensitivity to Aspergillus spp. was reported for children (n = 714) with an age
of 13 years in cohort in New Zealand measured by a skin prick test (SPT) and 2% was reported for
450 children and adults in the United Kingdom (Cullinan et al., 1997).
Occupational sensitisation against enzymes produced by Aspergillus species and their dust spores
have been reported in the literature (Cullinan et al., 1997; Bernstein et al., 1999).
In a study by Bindslev-Jensen et al. (2006), 400 consecutive adult subjects with diagnosed allergy
to inhalation allergens, food allergens, bee or wasp were enrolled and were skin prick tested against
19 different commercial enzymes used in the food industry (including three enzymes produced by
A. niger and seven enzymes produced by Aspergillus oryzae). Thirteen patients showing positive
results in the SPT were subsequently challenged orally with the respective enzymes in a double-blind,
placebo-controlled protocol. Only one reaction to a placebo challenge was seen. No positive challenges
to the enzymes positive in SPT.
The Panel considers that the allergenic risk of the novel food is not dissimilar as of other food
enzymes produced by Aspergillus.
4. Discussion
The NF is an enzyme preparation of prolyl-oligopeptidase produced with a genetically modiﬁed
A. niger strain. The composition of this enzyme preparation and its production process including a
submerged fermentation do not raise safety concern. The information provided on the genetic
modiﬁcation carried out to obtain the producer strain GEP-44, on the genetic stability of the production
microorganism, the expression of the recombinant protein and on the absence of recombinant DNA in
the novel food, do not raise safety concerns.
The target population is the general adult population. The NF is intended to be consumed just before,
during or directly after a meal. The applicant recommends an intake of 40 PPU Tolerase® G per meal
(= 0.916 g enzyme preparation) and daily maximum intake of 120 PPU (2x10E6 PPI) Tolerase® G
(approximately 2.7 g enzyme preparation) which would correspond to three intakes (three meals) per day.
The results from a bacterial reverse mutation test and of an in vitro chromosome aberration test
did not indicate genotoxicity.
Taking into account the intended maximum use level for Tolerase® G, its daily consumption would
correspond to 2,746 mg TOS per person or to 39.2 mg TOS/kg bw per day, when considering a default
body weight of 70 kg for adults. The margin between this value and the mid dose in the rats, which
caused effects attributable to the excess energy intake, is approximately 45. Noting this margin, the
Panel considers that it is unlikely that such effects would occur in human at the intended use levels.
5. Conclusions
The Panel concludes that the NF, Tolerase® G, is safe for the intended use at the intended use
level.
Documentation provided to EFSA
1) Letter from the European Commission to the European Food Safety Authority with the
request for a scientiﬁc opinion on the safety of proline-speciﬁc oligopeptidase as a novel food
ingredient. Ref. Ares(2015)5348394, dated 25/11/2015.
2) Dossier ‘Application for the approval of ToleraseTM G, a proline-speciﬁc oligopeptidase derived
from Aspergillus niger to be used as a food supplement aiding in the digestion of gluten’.
DSM no. 1146-001 received on 3 December 2015.
3) Dossier ‘Application for the approval of Tolerase® G, a proline speciﬁc oligopeptidase (prolyl
oligopeptidase) derived from Aspergillus niger to be used as an ingredient in food
supplements (‘Consolidated dossier Feb 2016’) received on 19 February 2016.
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4) On 13 June 2016 and 12 July 2016, EFSA sent requests to the applicant to provide
missing/complementary information.
5) On 11 July 2016, EFSA received the missing information as submitted by the applicant.
6) Initial assessment report carried out by the Food Safety Authority of France: ‘Opinion of the
National Agency for Food, Environmental and Occupational Health and Safety concerning a
request for authorisation to place on the market a novel food or food ingredient: enzyme
preparation containing a protease activity.’ Avis de i’Anses Saisine n° 2014-SA-0086 Saisines
liees n° 2013-SA-0112 et 2012-SA-0120.
7) Member States’ comments and objections.
8) Response by the applicant to the initial assessment report and the Member States’ comments
and objections.
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Abbreviations
bw bodyweight
CAS Chemical Abstracts Service
cGMP current Good Manufacturing Practice
FOB functional observation battery
GLP Good Laboratory Practice
GM genetically modiﬁed
GMM genetically modiﬁed microorganism
GMO genetically modiﬁed organism
GSRS gastrointestinal symptom rating scale
HACCP Hazard Analysis of Critical Control Points
ISO International Organization for Standardization
MCH mean corpuscular haemoglobin
NDA EFSA Panel on Dietetic Products, Nutrition and Allergies
NF novel food
OECD Organisation for Economic Co-operation and Development
PCR polymerase chain reaction
pNA p-nitroanilide
PPI protease picomole international
PPU prolyl peptidase units or proline protease units
QPS Qualiﬁed presumption of safety (QPS)
SD standard deviation
SDS–PAGE sodium dodecyl sulfate–polyacrylamide gel electrophoresis
SPT skin prick test
TOS total organic solids
Z-Gly-Pro-pNA carbobenzoxy-glycyl-proline-p-nitroanilide
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